{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T07:47:49Z","timestamp":1792223269828,"version":"4.4.0"},"reference-count":33,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2019,8,15]],"date-time":"2019-08-15T00:00:00Z","timestamp":1565827200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0221123","type":"journal-article","created":{"date-parts":[[2019,8,15]],"date-time":"2019-08-15T17:44:31Z","timestamp":1565891071000},"page":"e0221123","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":21,"title":["Prospective evaluation of two screening methods for molecular testing of metastatic melanoma: Diagnostic performance of BRAF V600E immunohistochemistry and of a NRAS-BRAF fully automated real-time PCR-based assay"],"prefix":"10.1371","volume":"14","author":[{"given":"Audrey","family":"Vall\u00e9e","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Denis-Musquer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Herbreteau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Th\u00e9oleyre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Bossard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5865-3248","authenticated-orcid":true,"given":"Marc G.","family":"Denis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2019,8,15]]},"reference":[{"key":"pone.0221123.ref001","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.molonc.2007.12.003","article-title":"Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site","volume":"1","author":"A Platz","year":"2008","journal-title":"Mol Oncol"},{"key":"pone.0221123.ref002","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1200\/JCO.2011.41.2452","article-title":"BRAF\/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma","volume":"30","author":"M Colombino","year":"2012","journal-title":"J Clin Oncol"},{"key":"pone.0221123.ref003","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1200\/JCO.2015.62.9345","article-title":"Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib","volume":"34","author":"GV Long","year":"2016","journal-title":"J Clin Oncol"},{"key":"pone.0221123.ref004","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1093\/annonc\/mdx339","article-title":"Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study","volume":"28","author":"PB Chapman","year":"2017","journal-title":"Ann Oncol"},{"key":"pone.0221123.ref005","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1158\/1078-0432.CCR-13-3122","article-title":"BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact","volume":"20","author":"H Rizos","year":"2014","journal-title":"Clin Cancer Res"},{"key":"pone.0221123.ref006","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1186\/s12885-017-3529-5","article-title":"Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care","volume":"17","author":"MV Heppt","year":"2017","journal-title":"BMC Cancer"},{"key":"pone.0221123.ref007","doi-asserted-by":"crossref","first-page":"387","DOI":"10.21037\/atm.2017.06.09","article-title":"Overcoming resistance to BRAF inhibitors","volume":"5","author":"I Arozarena","year":"2017","journal-title":"Ann Transl Med"},{"key":"pone.0221123.ref008","doi-asserted-by":"crossref","first-page":"3182","DOI":"10.1200\/JCO.2012.47.7836","article-title":"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin","volume":"31","author":"FS Hodi","year":"2013","journal-title":"J Clin Oncol"},{"key":"pone.0221123.ref009","article-title":"Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine","author":"L Cheng","year":"2018","journal-title":"Mod Pathol"},{"key":"pone.0221123.ref010","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s00401-011-0887-y","article-title":"Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases","volume":"123","author":"D Capper","year":"2012","journal-title":"Acta Neuropathol"},{"key":"pone.0221123.ref011","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.5858\/arpa.2011-0505-OA","article-title":"Multisite analytic performance studies of a real-time polymerase chain reaction assay for the detection of BRAF V600E mutations in formalin-fixed, paraffin-embedded tissue specimens of malignant melanoma","volume":"136","author":"S Anderson","year":"2012","journal-title":"Arch Pathol Lab Med"},{"key":"pone.0221123.ref012","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.mcp.2004.05.004","article-title":"Real-time allele-specific amplification for sensitive detection of the BRAF mutation V600E","volume":"18","author":"A Jarry","year":"2004","journal-title":"Mol Cell Probes"},{"key":"pone.0221123.ref013","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jmoldx.2012.09.001","article-title":"Detection of BRAF p.V600E mutations in melanomas: comparison of four methods argues for sequential use of immunohistochemistry and pyrosequencing","volume":"15","author":"E Colomba","year":"2013","journal-title":"J Mol Diagn"},{"key":"pone.0221123.ref014","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/jid.2014.366","article-title":"Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma.","volume":"135","author":"AE Siroy","year":"2015","journal-title":"J Invest Dermatol"},{"key":"pone.0221123.ref015","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/j.humpath.2015.04.012","article-title":"Utility of BRAF V600E Immunohistochemistry Expression Pattern as a Surrogate of BRAF Mutation Status in 154 Patients with Advanced Melanoma","volume":"46","author":"MT Tetzlaff","year":"2015","journal-title":"Hum Pathol"},{"key":"pone.0221123.ref016","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1111\/cup.12364","article-title":"Validation of the VE1 immunostain for the BRAF V600E mutation in melanoma","volume":"41","author":"MV Pearlstein","year":"2014","journal-title":"J Cutan Pathol"},{"key":"pone.0221123.ref017","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.yexmp.2015.09.004","article-title":"Multi-center evaluation of the novel fully-automated PCR-based Idylla BRAF Mutation Test on formalin-fixed paraffin-embedded tissue of malignant melanoma","volume":"99","author":"L Melchior","year":"2015","journal-title":"Exp Mol Pathol"},{"key":"pone.0221123.ref018","doi-asserted-by":"crossref","first-page":"e0153576","DOI":"10.1371\/journal.pone.0153576","article-title":"Detection of BRAF Mutations Using a Fully Automated Platform and Comparison with High Resolution Melting, Real-Time Allele Specific Amplification, Immunohistochemistry and Next Generation Sequencing Assays, for Patients with Metastatic Melanoma","volume":"11","author":"A Harle","year":"2016","journal-title":"PLoS One"},{"key":"pone.0221123.ref019","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jmoldx.2015.12.005","article-title":"Multicenter Evaluation of a Novel Automated Rapid Detection System of BRAF Status in Formalin-Fixed, Paraffin-Embedded Tissues.","volume":"18","author":"AI Schiefer","year":"2016","journal-title":"J Mol Diagn"},{"key":"pone.0221123.ref020","doi-asserted-by":"crossref","first-page":"44","DOI":"10.2340\/00015555-2738","article-title":"Evaluation of a Rapid, Fully Automated Platform for Detection of BRAF and NRAS Mutations in Melanoma","volume":"98","author":"F Barel","year":"2018","journal-title":"Acta Derm Venereol"},{"key":"pone.0221123.ref021","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1136\/jclinpath-2017-204356","article-title":"Validating a fully automated real-time PCR-based system for use in the molecular diagnostic analysis of colorectal carcinoma: a comparison with NGS and IHC","volume":"70","author":"R Colling","year":"2017","journal-title":"J Clin Pathol"},{"key":"pone.0221123.ref022","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1136\/jclinpath-2017-204629","article-title":"Clinical performance evaluation of the Idylla NRAS-BRAF mutation test on retrospectively collected formalin-fixed paraffin-embedded colorectal cancer tissue","volume":"71","author":"L Johnston","year":"2017","journal-title":"J Clin Pathol"},{"key":"pone.0221123.ref023","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1186\/s13104-017-2650-5","article-title":"Efficient treatment of a metastatic melanoma patient with a combination of BRAF and MEK inhibitors based on circulating tumor DNA analysis: a case report","volume":"10","author":"G Quereux","year":"2017","journal-title":"BMC Res Notes"},{"key":"pone.0221123.ref024","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.lungcan.2017.10.010","article-title":"Treatment of a NSCLC patient with osimertinib based on the detection of the EGFR T790M resistance mutation in cerebrospinal fluid","volume":"114","author":"S Theoleyre","year":"2017","journal-title":"Lung Cancer"},{"key":"pone.0221123.ref025","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1056\/NEJMoa050092","article-title":"Distinct sets of genetic alterations in melanoma","volume":"353","author":"JA Curtin","year":"2005","journal-title":"N Engl J Med"},{"key":"pone.0221123.ref026","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/exd.13472","article-title":"BRAF mutations might be more common than supposed in vulvar melanomas","volume":"27","author":"S Wylomanski","year":"2018","journal-title":"Exp Dermatol"},{"key":"pone.0221123.ref027","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/exd.12584","article-title":"Comparative analysis of BRAF, NRAS and c-KIT mutation status between tumor tissues and autologous tumor cell-lines of stage III\/IV melanoma","volume":"24","author":"AC Knol","journal-title":"Exp Dermatol"},{"key":"pone.0221123.ref028","doi-asserted-by":"crossref","first-page":"808","DOI":"10.3892\/or.2014.3265","article-title":"Younger age at the time of first metastasis in BRAF-mutated compared to BRAF wild-type melanoma patients","volume":"32","author":"M Saint-Jean","journal-title":"Oncol Rep"},{"key":"pone.0221123.ref029","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.jss.2016.04.029","article-title":"Immunohistochemistry as a reliable method for detection of BRAF-V600E mutation in melanoma: a systematic review and meta-analysis of current published literature","volume":"203","author":"MA Anwar","year":"2016","journal-title":"J Surg Res"},{"key":"pone.0221123.ref030","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/PAS.0b013e31826485c0","article-title":"Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma","volume":"37","author":"GV Long","year":"2013","journal-title":"Am J Surg Pathol"},{"key":"pone.0221123.ref031","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.jmoldx.2018.05.008","article-title":"Multicenter Evaluation of the Idylla NRAS-BRAF Mutation Test in Metastatic Colorectal Cancer.","volume":"20","author":"I Prieto-Potin","year":"2018","journal-title":"J Mol Diagn"},{"key":"pone.0221123.ref032","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/CMR.0000000000000421","article-title":"Rapid BRAF mutation tests in patients with advanced melanoma: comparison of immunohistochemistry, Droplet Digital PCR, and the Idylla Mutation Platform","volume":"28","author":"C Bisschop","year":"2018","journal-title":"Melanoma Res"},{"key":"pone.0221123.ref033","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1136\/jclinpath-2017-204579","article-title":"Financial implications of Idylla testing in colorectal cancer, lung cancer and melanoma: a French laboratory point of view","volume":"70","author":"G Le Flahec","year":"2017","journal-title":"J Clin Pathol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0221123","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T19:32:49Z","timestamp":1588966369000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0221123"}},"subtitle":[],"editor":[{"given":"Amanda Ewart","family":"Toland","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2019,8,15]]},"references-count":33,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2019,8,15]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0221123","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,15]]}}}